Telix has announced it has entered into an agreement to acquire QSAM Biosciences, Inc. and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

To read more please visit:

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

Source: Telix